We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Horizon Discovery and Mammoth Biosciences Collaborate To Improve Biotherapeutic Production

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Horizon Discovery and Mammoth Biosciences Collaborate To Improve Biotherapeutic Production"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery, a global leader in the application of gene editing and gene modulation technologies, has announced that it has signed a collaboration and license agreement with Mammoth Biosciences, to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.

Horizon’s bioproduction business unit currently offers the biopharmaceutical industry a well-characterized CHO cell line and customized services to facilitate the development and identification of best performing gene-edited cell lines.

Under the terms of the agreement, the companies will collaborate to optimize certain CRISPR tools to rapidly develop proprietary CHO cell lines. In these cell lines, selected genes are “knocked out” to improve performance parameters such as increasing productivity or reducing naturally occurring contaminants to facilitate purification.

Mammoth Biosciences is a San Francisco based biotech company that has built the first CRISPR-based detection platform for diagnostics. Mammoth’s novel CRISPR platform can be used and built on by partners across a variety of industries. Its DETECTR biosensing platform acts as a search engine for biology, capable of sensing any nucleic acid-based biomarker, including markers for early detection of diseases ranging from infections to cancer.